TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26148063
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis after umbilical cord clamping
Study: 21154195
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (83 μg or 3,332 IU daily for 1 year)
Study: 9589267
Drug: Buprenorphine 2
Normalized name: buprenorphine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 2 mg
Study: 10463317
Drug: Buprenorphine 8
Normalized name: buprenorphine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 8 mg
Study: 21904686
Drug: Buprenorphine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (2 mg and 8 mg)
Study: 10516884
Drug: Pramipexole 0.75
Normalized name: pramipexole 0.75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 0.75 mg/d
Study: 9214527
Drug: Pramipexole 4.5
Normalized name: pramipexole 4.5 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 4.5 mg/d
Study: 7011249
Drug: Low-dose haloperidol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose haloperidol
Study: 27140801
Drug: Thrombomodulin alfa
Normalized name: Thrombomodulin Alfa
DrugBank: Thrombomodulin Alfa (DB05777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombomodulin alfa (0.02 mg/kg)
Study: 25466666
Drug: Glutamine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (30 g/d)
Study: 29104459
Drug: Placebo (casein,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (casein, 30 g/d)
Study: 25039544
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline
Study: 11280555
Drug: Alosetron 1
Normalized name: alosetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron 1 mg b.i.d.
Study: 9402351
Drug: Furazolidone combined
Normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furazolidone combined with bismuth subsalicylate and amoxicillin
Study: 9402351
Drug: Testing for
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testing for antibodies to H. pylori
Study: 8219653
Drug: Normal vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal vs elevated urinary albumin excretion
Study: 8219653
Drug: Increased urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased urinary albumin and alpha-1-microglobulin excretion
Study: 7272174
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 30 mg
Study: 3304705
Drug: N-acetylcysteine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine 100 mg/kg
Study: 23958608
Drug: Ice pack
Normalized name: Ice Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice pack therapy for 10 minutes
Study: 23958608
Drug: Ice pack
Normalized name: Ice Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice pack therapy for 20 minutes
Study: 23958608
Drug: Ice pack
Normalized name: Ice Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice pack therapy for 30 minutes
Study: 18996379
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy with porfimer sodium combined with acid suppression (PHOPDT)
Study: 18996379
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole twice daily (control)
Study: 8378890
Drug: Breast‐preserving therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast‐preserving therapy (BCT)
Study: 3137593
Drug: Intravenous nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous nicotine (0.5 microgram/kg/min)
Study: 23190756
Drug: Low amount
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low amount of dairy food (LD), equivalent to ≤238 mL/d milk
Study: 22097203
Drug: Calcichew D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcichew D3 Tablet
Study: 22097203
Drug: Calcichew D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcichew D3 Tablet and Xianling Gubao Capsule
Study: 22097203
Drug: Calcichew D5
Normalized name: VITAMIN D5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcichew D5 Tablet and embedding thread according to staging and wholism syndrome differentiation
Study: 19541504
Drug: Placebo (220
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (220 mg corn starch)
Study: 16274713
Drug: Heat therapy
Normalized name: CVS Neck Arm & Leg Heat Therapy Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat therapy (50 degrees C for 30s, applied once)
Study: 16274713
Drug: Glucantime therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucantime therapy (antimonial, administered for 20 days)
Study: 23746110
Drug: Heat therapy
Normalized name: CVS Neck Arm & Leg Heat Therapy Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat therapy
Study: 16274713
Drug: Glucantime therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucantime therapy
Study: 9028548
Drug: 5 micrograms/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 micrograms/kg/day G-CSF
Study: 9028548
Drug: 10 micrograms/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms/kg/day G-CSF
Study: 9028548
Drug: 16 micrograms/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 micrograms/kg/day G-CSF
Study: 9028548
Drug: Cost of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost of G-CSF
Study: 9028548
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of G-CSF
Study: 27781390
Drug: Multicomponent nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent nutritional supplement for 24 weeks
Study: 1970107
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone measurement
Study: 31317694
Drug: Frankincense consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frankincense consumption (500 mg pills, two times a day for 4 weeks)
Study: 2686417
Drug: Intravenous ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ciprofloxacin (200 mg every 12 hours)
Study: 2686425
Drug: Intravenous ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ceftazidime (1 g every eight hours)
Study: 2686417
Drug: Intravenous ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ceftazidime
Study: 29436868
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy (10 l/min)
Study: 22182228
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (VeC and CC)
Study: 14517188
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (C)
Study: 8222516
Drug: Noradrenaline infusion
Normalized name: noradrenaline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline infusion
Study: 15562199
Drug: HIM2 (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIM2 (0.125 mg/kg)
Study: 12547873
Drug: HIM2 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIM2 (0.5 mg/kg)
Study: 15562199
Drug: HIM2 (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIM2 (0.75 mg/kg)
Study: 9430857
Drug: Loop diuretics
Normalized name: LOOP DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop diuretics (torasemide, frusemide)
Study: 7900662
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone (7 mg/kg)
Study: 18339679
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg aspirin on alternate days
Study: 9010986
Drug: Dolasetron mesilate
Normalized name: Dolasetron mesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron mesilate 1.8 mg/kg
Study: 29905976
Drug: Rolapitant (IV)
DrugBank: Rolapitant (DB09291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rolapitant (IV) 18 mg
Study: 29905976
Drug: Rolapitant (IV)
DrugBank: Rolapitant (DB09291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rolapitant (IV) 36 mg
Study: 29905976
Drug: Rolapitant (IV)
DrugBank: Rolapitant (DB09291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rolapitant (IV) 54 mg
Study: 25660991
Drug: Tapering DMARDs
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapering DMARDs by 50% (arm 2)
Study: 25660991
Drug: Stopping DMARDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopping DMARDs after 6 months tapering (arm 3)
Study: 24518124
Drug: Irsogladine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irsogladine (4 mg/day)
Study: 7850821
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) monotherapy
Study: 20725056
Drug: Atenolol monotherapy
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol monotherapy
Study: 19571804
Drug: HCTZ +
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCTZ + atenolol combination therapy
Study: 19571804
Drug: Atenolol +
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol + HCTZ combination therapy
Study: 7623725
Drug: Pre-radiotherapy chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-radiotherapy chemotherapy (vincristine, procarbazine, methotrexate)
Study: 7623725
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose radiotherapy (25 Gy to the craniospinal axis)
Study: 7623725
Drug: Post-radiotherapy chemotherapy
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-radiotherapy chemotherapy (vincristine and CCNU for high risk children)
Study: 2259867
Drug: Amikacin 11
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin 11 mg/kg bw
Study: 2259867
Drug: Amikacin 15
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin 15 mg/kg bw
Study: 7377745
Drug: Sulfadiazine (SD)
Normalized name: Sulfadiazine
DrugBank: Sulfadiazine (DB00359)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfadiazine (SD) 500 mg twice daily
Study: 7377745
Drug: Sulfamethoxazole (SM)
Normalized name: Sulfamethoxazole
DrugBank: Sulfamethoxazole (DB01015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfamethoxazole (SM) 1000 mg twice daily
Study: 31991511
Drug: Vibegron 50
Normalized name: Vibegron
DrugBank: Vibegron (DB14895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vibegron 50 mg
Study: 31991511
Drug: Vibegron 100
Normalized name: Vibegron
DrugBank: Vibegron (DB14895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vibegron 100 mg
Study: 31991511
Drug: Vibegron 50
Normalized name: Vibegron
DrugBank: Vibegron (DB14895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vibegron 50 mg and 100 mg
Study: 27641003
Drug: Deferiprone 16.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferiprone 16.7 mg kg‐1
Study: 21244439
Drug: Kudzu extract
Normalized name: Aminobenzoic Acid/Black Cohosh Extract/Boron/Dong Quai Extract/Ginseng Extract, Korean/Hesperidin/Kudzu Extract/Licorice Extract/Resveratrol/Wild Yam Extract 50 MG-25 MG-25 MCG-25 MG-100 MG-50 MG-25 MG-37.5 MG-0.5 MG-25 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kudzu extract (total isoflavone dose of 750 mg/d)
Study: 19961042
Drug: eperisone 300
Normalized name: acetaminophen / phenyltoloxamine citrate Oral Tablet [Perisine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: eperisone 300 mg/day
Study: 19961042
Drug: eperisone 150
Normalized name: acetaminophen / phenyltoloxamine citrate Oral Tablet [Perisine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: eperisone 150 mg/day
Study: 18190257
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) once-daily therapy
Study: 3122575
Drug: Human menopausal
Normalized name: Human menopausal gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human menopausal gonadotropin (150 U administered hourly)
Study: 25761501
Drug: Before treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before treatment for intestinal parasites
Study: 25761501
Drug: After successful
Approvals — FDA: no, EMA: no, PMDA: no
Description: After successful antiparasitic treatment
Study: 23050945
Drug: Glucosamine (Artrox®)
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine (Artrox®) 625 mg twice daily
Study: 15908764
Drug: rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 10 mg once daily
Study: 15908764
Drug: ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine 300 mg once daily
Study: 12479049
Drug: External RF
Normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: External RF hyperthermia (ERFH) combined with alpha 1-adrenergic receptor blocker Terazosin for 12 weeks
Study: 2777428
Drug: Liquid-filled capsules
Normalized name: RP Scherer Paracetamol Liquid-Filled Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid-filled capsules (20 mg)
Study: 2777428
Drug: Slow-release tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release tablets (20 mg)
Study: 1120220
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 tablets
Study: 31345559
Drug: propofol +
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propofol + ketamine 0.4 mg/kg
Study: 7851554
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of laparoscopy and laparoscopic ultrasound
Study: 2693432
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course tobramycin therapy
Study: 30600526
Drug: Intranasal sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal sufentanil (0.4 μg/kg)
Study: 21319897
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) intervention
Study: 19843674
Drug: Energy intake
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy intake from a FFQ administered approximately five years after entry
Study: 9658729
Drug: Nadroparin (home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin (home treatment)
Study: 8018909
Drug: Intermittent cyclic
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent cyclic regimen of intermediate-dose methotrexate (MTX) plus 6-mercaptopurine (6MP)
Study: 8018909
Drug: Conventional continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional continuous administration of low dose of MTX plus 6MP
Study: 8018909
Drug: Three-drug induction
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug induction therapy consisting of vincristine (VCR), prednisone (PDN), and L-asparaginase (L-ASP)
Study: 4129562
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg dose of Delta 1 testololactone
Study: 4129562
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg dose of Delta 1 testololactone
Study: 8498662
Drug: Intravenous alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alfentanil (PCA)
Study: 3031226
Drug: Chest radiation
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chest radiation therapy (4,800 rad in a split-course scheme)
Study: 3031226
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without interruption (maintenance chemotherapy with cyclophosphamide and VP-16)
Study: 3031226
Drug: Preinduction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preinduction treatment volume or postinduction reduced tumor volume (radiation treatment portals based on tumor extent)
Study: 19147232
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide implant
Study: 16541243
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg caffeine
Study: 12842055
Drug: Urogynaecologist treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urogynaecologist treatment
Study: 8780282
Drug: Ondansetron (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (1, 4, or 8 mg intravenously before induction of anesthesia)
Study: 1621434
Drug: IgG-anticardiolipin-antibodies in
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG-anticardiolipin-antibodies in patients with cerebral and peripheral artery disease (group C)
Study: 1621434
Drug: IgG-anticardiolipin-antibodies in
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG-anticardiolipin-antibodies in patients with peripheral artery disease only (group B)
Study: 22449804
Drug: Xylitol lozenges
Normalized name: xylitol Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol lozenges (6 g/day) for 33 months
Study: 18848670
Drug: Quick Start
Normalized name: Cal-Quick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quick Start (QS) - immediate, directly observed OC pill ingestion in the clinic
Study: 18848670
Drug: Conventional Start
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Start (CS) - conventional initiation of the OC pill
Study: 11324096
Drug: Universally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universally administered classroom program
Study: 8983588
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (five different techniques used)
Study: 8983588
Drug: Three-dimensional treatment
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dimensional treatment planning system
Study: 1722779
Drug: HES‐A (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES‐A (500 ml daily for 9 days)
Study: 1722779
Drug: HES‐B (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES‐B (500 ml daily for 8 days)
Study: 7327086
Drug: Thrice weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice weekly levo‐alpha‐acetylmethadol (LAAM)
Study: 30182753
Drug: D3-Vitamin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: D3-Vitamin (100 μg/day)
Study: 26151421
Drug: 600,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600,000 IU intramuscular (i.m.)
Study: 26151421
Drug: 200,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200,000 IU intramuscular (i.m.)
Study: 26151421
Drug: 200,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200,000 IU oral (p.o.)
Study: 22872657
Drug: Slow intravenous
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow intravenous infusion of lactated Ringer solution (1.2 ± 0.3 litres)
Study: 22872657
Drug: Dehydration (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dehydration (no intravenous infusion)
Study: 19213607
Drug: Brachytherapy I-125
Normalized name: HSA I-125
DrugBank: Albumin iodinated I-125 serum (DB09429)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brachytherapy I-125 with rectal protection using hyaluronic acid (HA)
Study: 17941364
Drug: MimyX cream
Normalized name: MIMYX CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: MimyX cream (PDT or IPL)
Study: 15551893
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg midazolam (1 ml)
Study: 15551893
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg midazolam (1 ml)
Study: 23513246
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow (NHF) oxygen therapy at 30 L/min
Study: 23513246
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow (NHF) oxygen therapy at 40 L/min
Study: 23513246
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow (NHF) oxygen therapy at 50 L/min
Study: 21736780
Drug: Daily supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplemented with 600 μg retinol, 1·0 mg β‐carotene, 100 mg tocopherol, 300 mg ascorbic acid and 200 μg Se (Group A2)
Study: 21736780
Drug: Daily supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplemented with antioxidants (Groups B2 and C2)
Study: 19135997
Drug: Fluid administration
Normalized name: Fluid Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid administration greater than restriction limits
Study: 14551140
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg IDEC‐131/E6040
Study: 14551140
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg IDEC‐131/E6040
Study: 14551140
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg IDEC‐131/E6040
Study: 10609422
Drug: Interpersonal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal and social rhythm therapy (IPSRT)
Study: 9857856
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg imidapril
Study: 8803516
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg imidapril
Study: 8803516
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg imidapril